Direct Answer
SEC EDGAR classifies Becton Dickinson under SIC code 3841 (Surgical & Medical Instruments & Apparatus). Among Swoopr's S&P 500 Equal Weight companies, 84 others share that classification; by latest reported revenue, Becton Dickinson ranks 4 of 85. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes.
How Does Becton Dickinson Compare With Its Peers?
| Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|
| Medline Inc. (MDLN) | $28.4 billion FY2025 | 11.5% | 7.8% | 4069.4% |
| Stryker Corporation (SYK) | $25.1 billion FY2025 | 11.2% | 19.5% | 12.9% |
| 3M (MMM) | $24.9 billion FY2025 | 1.5% | 18.6% | 13.0% |
| Becton Dickinson (BDX) | $21.8 billion FY2025 | 8.2% | 11.8% | 7.7% |
| Boston Scientific (BSX) | $20.1 billion FY2025 | 19.9% | 18.0% | 14.4% |
| Baxter International (BAX) | $11.2 billion FY2025 | 5.7% | -2.7% | -8.5% |
| Solventum (SOLV) | $8.3 billion FY2025 | 0.9% | 26.2% | 18.7% |
| ResMed (RMD) | $5.1 billion FY2025 | 9.8% | 32.7% | 27.2% |
| Dexcom (DXCM) | $4.7 billion FY2025 | 15.6% | 19.6% | 17.9% |
| MiniMed Group Inc. (MMED) | $3.1 billion FY2026 | 14.3% | -6.1% | -10.7% |
| West Pharmaceutical Services (WST) | $3.1 billion FY2025 | 6.3% | 19.0% | 16.1% |
| Globus Medical Inc. (GMED) | $2.9 billion FY2025 | 16.7% | 16.3% | 18.3% |
| Insulet Corporation (PODD) | $2.7 billion FY2025 | 30.7% | 17.5% | 9.1% |
| Penumbra Inc. (PEN) | $1.4 billion FY2025 | 17.5% | 13.5% | 12.7% |
| Haemonetics Corporation (HAE) | $1.3 billion FY2026 | -2.0% | 11.7% | 0.0% |
| Embecta Corp. (EMBC) | $1.1 billion FY2025 | -3.8% | 22.4% | 8.8% |
| Alphatec Holdings Inc. (ATEC) | $764 million FY2025 | 25.0% | -10.7% | -18.8% |
| iRhythm Holdings Inc. (IRTC) | $747 million FY2025 | 26.2% | -7.7% | -6.0% |
| Bioventus Inc. (BVS) | $568 million FY2025 | -0.9% | 9.5% | 4.0% |
| AtriCure Inc. (ATRC) | $535 million FY2025 | 14.9% | -1.8% | -2.1% |
| Accuray Incorporated (ARAY) | $459 million FY2025 | 2.7% | 1.7% | -0.3% |
| MiMedx Group Inc (MDXG) | $419 million FY2025 | 20.0% | 15.3% | 11.6% |
| Tactile Systems Technology Inc. (TCMD) | $330 million FY2025 | 12.5% | 8.9% | 5.8% |
| AngioDynamics Inc. (ANGO) | $320 million FY2026 | 9.5% | -12.5% | -11.5% |
| PROCEPT BioRobotics Corporation (PRCT) | $308 million FY2025 | 37.2% | -33.7% | -0.0% |
| SkinHealth Systems Inc. (SKIN) | $301 million FY2025 | -10.0% | -6.9% | -3.2% |
| OrthoPediatrics Corp. (KIDS) | $236 million FY2025 | 15.4% | -16.6% | -16.8% |
| Cerus Corporation (CERS) | $234 million FY2025 | 16.1% | -3.7% | -6.7% |
| Treace Medical Concepts Inc. (TMCI) | $213 million FY2025 | 1.6% | -25.5% | -27.7% |
| SI-BONE Inc. (SIBN) | $201 million FY2025 | 20.2% | -11.1% | -9.4% |
| Heartflow Inc. (HTFL) | $176 million FY2025 | 39.9% | -36.4% | -66.3% |
| Neuronetics Inc. (STIM) | $149 million FY2025 | 99.2% | -21.1% | -26.1% |
| InfuSystems Holdings Inc. (INFU) | $143 million FY2025 | 6.4% | 8.3% | 4.6% |
| Xtant Medical Holdings Inc. (XTNT) | $134 million FY2025 | 14.2% | 5.4% | 0.0% |
| OraSure Technologies Inc. (OSUR) | $115 million FY2025 | -38.1% | -62.6% | -59.8% |
| Anika Therapeutics Inc. (ANIK) | $113 million FY2025 | -5.9% | -9.8% | -9.8% |
| Beta Bionics Inc. (BBNX) | $100 million FY2025 | 53.9% | -71.5% | -73.0% |
| Neuropace Inc. (NPCE) | $100 million FY2025 | 25.1% | -16.3% | -21.5% |
| Kestra Medical Technologies Ltd. (KMTS) | $95 million FY2026 | 59.0% | -141.6% | -138.4% |
| Pulmonx Corporation (LUNG) | $90 million FY2025 | 8.0% | -59.3% | -59.7% |
| Delcath Systems Inc. (DCTH) | $85 million FY2025 | 129.1% | 0.8% | 3.2% |
| iRadimed Corporation (IRMD) | $84 million FY2025 | 14.4% | 31.2% | 26.8% |
| TELA Bio Inc. (TELA) | $80 million FY2025 | 15.8% | -42.0% | -48.3% |
| Sight Sciences Inc. (SGHT) | $77 million FY2025 | -3.1% | -48.0% | -49.7% |
| Avita Medical Inc. (RCEL) | $72 million FY2025 | 11.5% | -59.4% | -67.8% |
| Pro-Dex Inc. (PDEX) | $67 million FY2025 | 23.7% | 16.1% | 13.5% |
| LENSAR Inc. (LNSR) | $58 million FY2025 | 9.2% | -42.1% | -58.7% |
| CVRx Inc. (CVRX) | $57 million FY2025 | 10.4% | -90.5% | -94.1% |
| Apyx Medical Corporation (APYX) | $53 million FY2025 | 9.9% | -12.2% | -21.2% |
| Carlsmed Inc. (CARL) | $51 million FY2025 | 85.9% | -60.5% | -58.7% |
| Shoulder Innovations Inc. (SI) | $47 million FY2025 | 49.6% | -55.6% | -85.3% |
| TriSalus Life Sciences Inc. (TLSI) | $45 million FY2025 | 53.4% | -59.7% | -86.9% |
| SANUWAVE Health Inc. (SNWV) | $44 million FY2025 | 35.0% | 11.2% | 26.8% |
| KORU Medical Systems Inc. (KRMD) | $41 million FY2025 | 22.2% | -7.2% | -6.4% |
| Utah Medical Products Inc. (UTMD) | $39 million FY2025 | -5.8% | 29.6% | 29.3% |
| Retractable Technologies Inc. (RVP) | $38 million FY2025 | 15.8% | -55.3% | -32.8% |
| Cytosorbents Corporation (CTSO) | $37 million FY2025 | 4.1% | -39.8% | -22.1% |
| ClearPoint Neuro Inc. (CLPT) | $37 million FY2025 | 17.8% | -65.4% | -69.1% |
| Orchestra BioMed Holdings Inc. (OBIO) | $33 million FY2025 | 1169.2% | -154.7% | -157.4% |
| Sensus Healthcare Inc. (SRTS) | $27 million FY2025 | -34.3% | -37.5% | -28.1% |
| Spectral AI Inc. (MDAI) | $20 million FY2025 | -33.6% | -43.8% | -38.5% |
| Sonoma Pharmaceuticals Inc. (SNOA) | $20 million FY2026 | 36.7% | -12.6% | 0.0% |
| Nephros Inc. (NEPH) | $19 million FY2025 | 32.7% | 6.1% | 6.4% |
| Vivos Therapeutics Inc. (VVOS) | $17 million FY2025 | 16.0% | -114.1% | -121.4% |
| NexGel Inc (NXGL) | $11 million FY2025 | 31.5% | -29.3% | -26.3% |
| NeuroOne Medical Technologies Corporation (NMTC) | $9 million FY2025 | 163.5% | -46.5% | -39.6% |
| Beyond Air Inc. (XAIR) | $8 million FY2026 | 107.3% | -378.2% | -433.0% |
| INVO Fertility Inc. (IVF) | $7 million FY2025 | 4.7% | -105.8% | 340.9% |
| Cerenome Inc. (CNSY) | $5 million FY2025 | -10.5% | -293.5% | -429.4% |
| Lucid Diagnostics Inc. (LUCD) | $5 million FY2025 | 8.3% | -1054.8% | -1232.7% |
| Tenon Medical Inc. (TNON) | $4 million FY2025 | 20.4% | -324.3% | -318.4% |
| Intelligent Bio Solutions Inc. (INBS) | $3 million FY2025 | -1.9% | -349.8% | -346.2% |
| Femasys Inc. (FEMY) | $2 million FY2025 | 40.8% | -767.0% | -812.3% |
| SeaStar Medical Holding Corporation (ICU) | $1 million FY2025 | 814.1% | -986.6% | -984.6% |
| RenovoRx Inc. (RNXT) | $1 million FY2025 | 2511.6% | -1114.0% | -994.5% |
| SiNtx Technologies Inc. (SINT) | $1 million FY2025 | -64.7% | -1053.1% | -1018.1% |
| Co-Diagnostics Inc. (CODX) | $622,489 FY2025 | -84.1% | -8058.8% | -7550.3% |
| Pulse Biosciences Inc (PLSE) | $350,000 FY2025 | n/a | -21982.6% | -20794.6% |
| Bluejay Diagnostics Inc. (BJDX) | $249,040 FY2022 | n/a | -3741.5% | -3733.1% |
| Profusa Inc. (PFSA) | $100,000 FY2024 | n/a | -4500.0% | -9230.0% |
| PAVmed Inc. (PAVM) | $71,000 FY2025 | -97.6% | -30712.7% | -5315.5% |
| Adagio Medical Holdings Inc (ADGM) | $0 FY2025 | n/a | n/a | n/a |
| Aethlon Medical Inc. (AEMD) | $0 FY2024 | -100.0% | n/a | n/a |
| Autonomix Medical Inc. (AMIX) | $0 FY2026 | n/a | n/a | n/a |
| Fractyl Health Inc. (GUTS) | $0 FY2025 | -100.0% | n/a | n/a |
Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care.
How Does Becton Dickinson Rank Among All SEC Filers in Its Industry Code?
81 companies with annual reports in Swoopr's SEC dataset share SIC code 3841 (Surgical & Medical Instruments & Apparatus), a wider group than the S&P 500 Equal Weight companies above. Ranks run from 1 (highest) and use each company's latest fiscal year, in U.S. dollars.
| Measure | Becton Dickinson | Median of filers | Rank |
|---|---|---|---|
| Revenue | $21.8 billion | $85 million | 4 of 81 |
| Revenue growth | 8.2% | 14.7% | 53 of 78 |
| Operating margin | 11.8% | -16.6% | 16 of 81 |
| Net margin | 7.7% | -18.8% | 19 of 81 |
A SIC code reflects the filer's main business as the SEC records it, so the group mixes companies of very different size; the median is a better guide than the average, and a rank near the top by revenue says nothing about quality.
Where These Numbers Come From
Every figure on this page is a value Becton Dickinson reported in its own SEC filings, read from the SEC's XBRL data (accession 0000010795-25-000099 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
Who are Becton Dickinson's competitors?
Companies sharing Becton Dickinson's SEC classification (SIC code 3841 (Surgical & Medical Instruments & Apparatus)) include Medline Inc. (MDLN), Stryker Corporation (SYK), 3M (MMM), Boston Scientific (BSX), Baxter International (BAX). Its 10-K names the competitors it considers most relevant.
How does Becton Dickinson compare with its peers on margins?
Becton Dickinson's fiscal 2025 operating margin was 11.8%, against a peer median of -18.8%.
How are these peers chosen?
By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict.
How does Becton Dickinson rank among all companies in its SEC industry?
Among 81 SEC filers under SIC code 3841, Becton Dickinson ranks 4 by latest revenue, and 16 of 81 by operating margin (11.8% against a median of -16.6%).